Peter Attia· MD
semia blue type will be approved uh in the next year as a once a week drug the way we use it for diabetes and at a higher dose 2.4 milligrams rather than one milligram for the top dose and you know it's shown it's just best ever wage reduction and you know it's sort of an alternative to to bariatric surgery for these you know really overweight patients and wow i didn't realize that so you're telling me that you can now take a glp-1 agonist once a week with a sub-q injection and achieve comparable levels to the normal daily injected routine because that's historically been one of the barriers better better cardiovascular reduction it reduces heart attacks throughout cardiovascular death better than the daily one the laraglia type these are also revolutionary drugs but the cool thing they're very safe otherwise you know and whereas the sglt2 inhibitors you kind of reduce heart failure and renal failure and overall cardiovascular mortality and all cause mortality in sicker people this reduces more than atherosclerotic cardiovascular disease it has a stronger effect on mi stroke and you know those ruptured plaques we're talking about at the beginning they cause weight reduction from two different mechanisms of action they improve cardiovascular prognosis from do different mechanisms of action and they really work well together it's a phenomenal combination